Raltegravir resistance in the cerebrospinal fluid

B Mora-Peris; N E Mackie; D Suan; D A Cooper; B J Brew; A Winston

doi:10.1007/s15010-013-0409-z

Raltegravir resistance in the cerebrospinal fluid

Infection. 2013 Jun;41(3):731-4. doi: 10.1007/s15010-013-0409-z. Epub 2013 Feb 3.

Authors

B Mora-Peris¹, N E Mackie, D Suan, D A Cooper, B J Brew, A Winston

Affiliation

¹ Department of Medicine, Faculty of Medicine, Imperial College London, St Mary's Hospital Campus, Norfolk Place, London, W2 1PG, UK. b.mora-peris@imperial.ac.uk

PMID: 23378293
DOI: 10.1007/s15010-013-0409-z

Abstract

We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

AIDS Dementia Complex / drug therapy
AIDS Dementia Complex / virology*
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / pharmacology*
Brain / diagnostic imaging
Cerebrospinal Fluid / virology*
Drug Resistance, Viral*
HIV / drug effects*
HIV / isolation & purification
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Plasma / virology
Pyrrolidinones / administration & dosage
Pyrrolidinones / pharmacology*
Radiography
Raltegravir Potassium

Substances

Anti-HIV Agents
Pyrrolidinones
Raltegravir Potassium